ELRIG Drug Discovery

Listen to our talk, view our posters and meet our team!

Come and visit our team at our stand #G1 to discuss how bit.bio offers partnering opportunities that affords access to the most relevant parental human cell types and corresponding disease models. These models are physiologically relevant and highly characterised, offering predictive, in vitro, human cells for early drug discovery, phenotypic screening, and high-content imaging applications.

Workshop

"From Target ID to Candidate Selection | Building Robust Early-Stage Drug Discovery Workflows with Precision Reprogrammed Human iPSC-derived Cells"

Moderated by Javier Conde-Vancells, PhD, Director of Product Management, bit.bio

Workshop Highlights:
This workshop has been specially curated for the ELRIG audience, offering scientists an exclusive look into the latest advancements in human induced pluripotent stem cell (iPSC) -derived cell technologies, and their application in high throughput screens in early-stage drug discovery. Anyone attending this workshop will gain a unique insight into real-world applications of reprogrammed iPSC-derived models of human disease, and how these tools are being used to drive advancement throughout early-stage drug discovery, from target identification to lead optimisation.

• Talk 1 "Harnessing CRISPR-Ready ioCells for Drug Discovery in Neurodegenerative Diseases"
  Speaker| Sejla Salic-Hainzl, PhD |Vice President of R&D, bit.bio discovery
  Sejla Salic-Hainzl will showcase pioneering human iPSC-derived neuronal cells that stably express Cas9, called ioCRISPR-Ready Cells™, that enable the generation of readouts from CRISPR knockout experiments without the need for iPSC differentiation or guide delivery optimisation.
• Talk 2 "Developing CRISPR Screens in Human iPSC-derived Neurons for Identifying Druggable Targets for Neurodegeneration"
  Speaker | Luca Crepaldi, PhD | Group Leader, Discovery Screening, bit.bio
  Dr Crepaldi will dive into two recent publications utilising pooled and arrayed CRISPR knockout screens with ioCRISPR-Ready Cells to identify druggable targets for neurodegenerative conditions. 
• Talk 3 "Case Studies of the Use of Next-generation Human iPSC-derived Cells for Lead Generation in Drug Discovery"
  Speaker | Dominic Hussey, PhD | Senior Director of Sales, bit.bio
  Dr Hussey will highlight how precision cell reprogramming is solving existing challenges surrounding the generation of in vitro iPSC-derived disease models, and highlight recent success stories that utilised this burgeoning technology to advance the generation of new antisense oligonucleotide therapeutic leads for genetic diseases like Duchenne Muscular Dystrophy and Autism Spectrum Disorder.
  
  

Flash poster presentation!

Poster Title: "CRISPR Screening in iPSC-derived Microglia for Drug Target Discovery and Validation"
Speaker | Ann Byrne | Business Development Associate, bit.bio discovery
Thursday October 19th | 13.00 – 13.50 BST
Learning zone for early career professionals